

1 **Supplemental Figure Legend**

2 **Fig. S1. The elevated METTL14-mediated RNA m6A modification in isolated**
3 **glomeruli from ADR-treated mice and diabetic db/db mice.** (A) The m6A levels of
4 total RNAs in isolated glomeruli from kidneys of ADR-treated mice and their
5 corresponding controls quantified by colorimetric ELISA assay. (n=4). (B) The m6A
6 contents of total RNAs in isolated glomeruli from kidneys of diabetic db/db mice and
7 control db/m mice. (n=4). (C) Quantitative RT-PCR analysis of major methyltransferases
8 and demethyltransferases in isolated glomeruli from mice with ADR treatment or normal
9 controls. (n=4.) (D) Quantitative RT-PCR analysis of major m6A modifying enzymes in
10 isolated glomeruli from db/db mice compared with control db/m mice. (n=4). (E)
11 Representative western blots and statistical analysis of METTL14 in isolated glomeruli
12 from kidneys of saline- or ADR-treated mice. (n=4). (F) Representative western blots and
13 statistical analysis of METTL14 in isolated glomeruli from kidneys of db/db mice and
14 control db/m mice. (n=4). Data are presented as mean \pm SEM. *P < 0.05, **P < 0.01 vs.
15 control group.

16 **Fig. S2. The up-regulated RNA m6A levels in human cultured podocytes under ADR**
17 **or AGE condition.** (A) The m6A levels of total RNAs in human cultured podocytes with
18 0.4 μ g/ml ADR treatment and their normal controls quantified by colorimetric ELISA
19 assay. (n=6). (B) The m6A contents of total RNAs in human cultured podocytes treated
20 with 50 μ g/ml AGE or BSA. (n=6).

1 **Fig. S3. The decreased m6A modification of Sirt1 mRNA in isolated glomeruli of**
2 **mice with podocyte-specific METTL14 deletion.** Relative methylated Sirt1 mRNA
3 levels in isolated glomeruli from METTL14^{flox/flox}/Cre⁺ mice compared with those from
4 wild-type mice. (n=4).